Registered title, quoted from ClinicalTrials.gov
Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations
An open trial on lung cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07336732, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 5
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (5 points)Hide the checklist
18 years to Not stated; sex: all
Registered eligibility fields
Histologically or cytologically confirmed, unresectable locally advanced (Stage IIIB or IIIC) or metastatic (Stage IV) non-squamous non-small cell lung cancer (NSCLC).
Inclusion criterion 2
ECOG PS ≤1.
Inclusion criterion 6
At least one measurable lesion as defined by RECIST v1.1.
Inclusion criterion 5
History of another active malignancy within the past 5 years (except for specific cured cancers).
Exclusion criterion 6
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; earlier treatment; blood tests: counts, liver and kidney function; pregnancy, breastfeeding and contraception.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07336732, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Age ≥18 years at the time of ICF signing.
- Histologically or cytologically confirmed, unresectable locally advanced (Stage IIIB or IIIC) or metastatic (Stage IV) non-squamous non-small cell lung cancer (NSCLC).
- Confirmed EGFR atypical mutation.
- No prior systemic therapy for locally advanced or metastatic NSCLC.
- At least one measurable lesion as defined by RECIST v1.1.
- ECOG PS ≤1.
- Life expectancy≥12 weeks.
- Adequate organ function confirmed within 7 days prior to the first dose of study treatment
- Female participants must use adequate contraceptive measures during study participation and for 90 days after the last dose of study treatment and must not be breastfeeding; female subjects not of childbearing potential must meet at least one of the following criteria at screening: Postmenopausal status; Documentation of irreversible surgical sterilization.
- Non-sterilized males: Abstinence or contraception use; No sperm donation.
- Willing and able to provide signed ICF and to comply with all requirements and restrictions listed in the ICF and this study protocol.
Exclusion Criteria:
- Presence of specific genetic alterations for which approved targeted therapies are available.
- Recent participation (within 28 days) in another interventional clinical trial.
- Major surgery within 28 days prior to study entry or planned during the study period.
- Recent use of anti-tumor traditional proprietary medicine or local anti-tumor therapy.
- Need for specific concomitant medications (e.g., metformin) that cannot be paused during the study.
- History of another active malignancy within the past 5 years (except for specific cured cancers).
- Toxicities from prior therapy have not recovered to acceptable levels.
- Presence of symptomatic or uncontrolled brain metastases, carcinomatous meningitis, or spinal cord compression.
- Symptomatic and uncontrolled third-space fluid accumulations (e.g., pleural effusion, ascites).
- Severe cardiovascular/cerebrovascular disease or risk factors (e.g., heart failure, history of myocardial infarction, QT prolongation, uncontrolled hypertension, etc.).
- History or presence of interstitial lung disease, or drug/radiation-related pneumonitis.
- Active autoimmune or inflammatory diseases.
- Active, uncontrolled infection (including HBV, HCV, HIV, syphilis, tuberculosis, etc.).
- Gastrointestinal disorders or surgery affecting drug ingestion or absorption.
- Active keratitis or ulcerative keratitis.
- History of hypersensitivity to the study drug, its analogs, or chemotherapy drugs (pemetrexed/platinum agents).
- Recent administration (within 30 days) of a live attenuated vaccine.
- Psychiatric disorders or substance abuse potentially affecting compliance.
- Any other condition deemed by the investigator as unsuitable for study participation.
Quoted from ClinicalTrials.gov, NCT07336732, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07336732, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.